Kornimate/medical-research-clean huggingface dataset:
expression pattern of hnrnph1 and hnrnpk genes in mpns

Conditions: Myeloproliferative Neoplasms (MPNs)

Summary: the aim of the study is to evaluate the expression pattern of heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) and k (hnrnpk) genes in myeloproliferative neoplasms as a possible indicator of disease progression and as a potential therapeutic target

self-renewing hematopoietic pluripotent stem cells can develop into either myeloid or lymphoid lineages. a diverse range of diseases known as myeloproliferative neoplasms (mpns) develop due to the aberrant proliferation of one or more terminal myeloid cell lines in the peripheral circulation. mpns come in four traditional forms: chronic myeloid leukaemia (cml), polycythaemia vera (pv), essential thrombocythemia (et), and primary myelofibrosis (pmf). chronic neutrophilic leukaemia (cnl), chronic eosinophilic leukaemia (cel), and mpn unclassifiable, were also included in the who classification. while pv, et, and pmf are bcr-abl1 negative, cml is bcr-abl1 positive. in eukaryotic cell's nucleus, many ribonucleoproteins (rnps) assemble on to recently produced transcripts. the heterogeneous nuclear ribonucleoproteins (hnrnps) are one type of rnps. some hnrnps are now known to play a role in the development of human hematologic malignancies. disease research is becoming more interested in how hnrnps control gene expression. numerous cancers exhibit changed hnrnps expression levels, which raises the possibility that they play a part in carcinogenesis. for instance, leukaemia cells showed downregulation of heterogeneous nuclear ribonucleoprotein k (hnrnpk). in vivo myeloproliferative neoplasm tumour growth was accelerated by hnrnpk knockdown. on the other hand, a study suggests that hnrnpk overexpression could accelerate cml development and thus a possible indicator of cml progression and a potential therapeutic target might be hnrnpk. moreover, one of the earliest rna-binding proteins (rbps) to be identified, heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) contributes to rna stabilization, rna editing, and rna modification. previous research has demonstrated that high levels of hnrnph1 expression leads to carcinogenesis by both upregulating the expression of oncogenes and downregulating the expression of tumour suppressor genes such p53, ron, and bcl-x. the investigators performed the study with the aim to study the expression level of heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) and k (hnrnpk) genes and their proteins in mpns and to investigate the association of hnrnph1 and hnrnpk with molecular diagnostic tests of mpns.

Eligibility criteria:
inclusion criteria: the study will be carried out on patients newly diagnosed with one of the myeloproliferative neoplasms based on who criteria for diagnosis of mpns whether males or females and of any age. exclusion criteria: * other malignancies. * patients on chemotherapy or radiotherapy. * autoimmune diseases.

Keywords: heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) heterogeneous nuclear ribonucleoprotein k (hnrnpk) myeloproliferative neoplasms (mpns)
posterior versus lateral laparoscopic mesh rectopexy for the management of complete rectal prolapse

Conditions: Posterior Laparoscopic; Lateral Laparoscopic; Rectopexy; Complete Rectal Prolapse

Summary: aim of the study is to evaluate the outcomes of two different methods of mesh placement during laparoscopic rectopexy for the management of complete rectal prolapse lateral versus posterior mesh rectopexy

rectal prolapse is the full-thickness prolapse of the rectum, in which the rectum passes externally beyond the anal sphincters. it is a somewhat rare condition, estimated to occur in less than 0.5% of the population. rectal prolapse has a 9:1 female predominance, and while it is occasionally seen in younger individuals, the incidence increases with age. surgical approaches for rectal prolapse can be divided into perineal and abdominal approaches. traditionally, a perineal procedure such as delorme or altemeir operation was commonly used in elderly or frail patients while an abdominal procedure such as rectopexy with or without resection was reserved for younger and fitter patients. the frequency of laparoscopic abdominal repair of rectal prolapse has increased in recent years, with mesh rectopexy being the most popular procedure. the mesh rectopexy operation was first described by ripstein10 in 1952. again, after mobilization of the rectum, an anterior sling of synthetic material (either absorbable or non-absorbable) is placed in front of the rectum and sutured to the sacral promontory. the rationale for this is to restore the natural curve of the rectum, which reduces the effect of downward abdominal pressure. the use of a non-elastic synthetic graft provides a firm anterior fascial support even in patients with significant pelvic floor descent, returning the rectum to a normal anatomical position. the act of mobilization, suture, and fibrosis keeps the rectum fixed in position as adhesions form, attaching the rectum to the presacral fascia. although sr is considered a good option for the cure of rectal prolapse/is in both men and women, some reviews of this procedure noted a better overall clinical outcome in men. this may be due to occult sphincter defects in women, and failure to detect these defects before surgery owing to the lack of routine endoanal ultrasonography in the earlier years of prolapse surgery

Eligibility criteria:
inclusion criteria: * age from 18 to 70 years. * both sexes. * patients with complete rectal prolapse. exclusion criteria: * unfit for surgery * impaired coagulation profile * contraindication of laparoscopy
intermittent oro-esophageal tube feeding in traumatic brain injury patients

Conditions: Traumatic Brain Injury

Summary: this was a multicenter randomized controlled study of 98 severe traumatic brain injury patients with tracheostomy. patients enrolled were divided randomly into the observation group with intermittent oro-esophageal tube feeding or the control group with nasogastric tube feeding for enteral nutrition support, respectively. nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared.

the safe and effective nutrition support for severe traumatic brain injury patients with tracheostomy continues to be a challenge. nasogastric tube feeding has been the mainstream choice in china but with the risk of complications. intermittent oro-esophageal tube feeding is an established modality of enteral nutrition support that can be used with routine treatment. this study reports the clinical outcomes of intermittent oro-esophageal tube feeding vs. nasogastric tube feeding, in patients receiving routine treatment. this was a multicenter randomized controlled study of 98 severe traumatic brain injury patients with tracheostomy. patients enrolled were divided randomly into the observation group with intermittent oro-esophageal tube feeding or the control group with nasogastric tube feeding for enteral nutrition support, respectively. nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, meeting the diagnosis of severe traumatic brain injury, confirmed through mri * score of glasgow coma scale (gcs) \<8; * presence of no contraindication for enteral nutrition; * with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications; * informed consent form was obtained from the patients' family members. exclusion criteria: * unable to cooperate in completing treatment and assessment due to personal reasons or other disorders; * complicated with other intracranial lesions, such as stroke; * with severe consciousness disorders caused by other diseases.
feasibility of remote jvp assessment

Conditions: Congestive Heart Failure

Summary: the jvphome is a novel medical device that utilizes machine vision in order to facilitate assessment of jugular venous pressure (jvp) height relative to the sternal angle with the ultimate goal of enabling remote jvp monitoring. the current study aims to evaluate the ability of the jvphome to enable remote identification of jvp height relative to ultrasound among congestive heart failure (chf) patients when the device is applied by the study team in the clinic.

chf is a common and devastating health problem estimated to affect upwards of 26 million individuals worldwide. following an initial hospitalization for heart failure, approximately 25% of patients are readmitted within the first 30 days of discharge. repeat heart failure hospitalizations are a major burden on both patients and healthcare systems. to date, there is an absence of non-invasive solutions proven to reduce the risk of re-hospitalization for chf. the key feature of the physical examination for assessing the volume status of chf patients is the jvp, which manifests as a biphasic pulsation along the neck. the height of the jvp relative to the sternal angle is a reflection of right atrial pressure, which increases in response to higher pressures transmitted from the left side of the heart. pathologic elevation of left sided heart pressures can result in fluid congestion in the lungs, which can cause patients to develop shortness of breath and reduced blood oxygen levels. although a crucial marker of volume status, accurate identification of the jvp can be challenging for physicians due to its pulsations often being subtle. the jvphome is a novel medical device designed to facilitate visualization of jvp height relative to the sternal angle through the use of machine vision. the current study aims to evaluate the jvphome in a clinic setting when the device is applied to chf patients by clinicians. following its application, the jvphome will be allowed to record a video of the jvp and images will subsequently be transmitted to a secure cloud and undergo analysis with machine vision software. jvp height of study participants will be concurrently assessed through the use of ultrasound (gold standard). clinicians that are blinded to ultrasound determined jvp height values will assess jvp height values remotely based on the machine enhanced images generated by the jvphome. analyses will then assess the accuracy of the jvphome relative to ultrasound and expert clinical assessment.

Eligibility criteria:
inclusion criteria: 1. age \>/= 18 years 2. congestive heart failure diagnosis receiving ongoing treatment 3. able to provide informed consent exclusion criteria: 1. conditions which preclude visualization of the jvp, including neck deformity, scarring, and facial hair

Keywords: jugular venous pressure, remote monitoring, machine vision, telemedicine
a trial of comparing the pathology status of lymphoseek®-identified sentinel lymph nodes relative to the pathological pathology status of nonsentinel lymph nodes in nodal staging of subjects with known cancer of the cervix who are undergoing lymph node dissection

Conditions: Uterine Cervical Neoplasms

Summary: prospective, open-label, within-patient, multi-center study of lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix. all subjects will receive a single dose of 50 µg lymphoseek radiolabeled with 2 mci (74 mbq) tc 99m.


Eligibility criteria:
inclusion criteria: * subject has provided written informed consent with hipaa authorization * has cervical cancer and is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan. * is at least 18 years of age at the time of consent * has an ecog performance status of grade 0 to 2 * has the following international federation of gynecology and obstetrics (figo) ia2-iia1staging. subjects with a single enlarged/suspicious node on pet/ct will still be considered eligible as consistent with figo guidelines. * if of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year exclusion criteria: * the subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to lymphoseek administration * has had previous surgery or radiation to node basins that would be involved in the ilm procedure * has a known allergy to dextran * is breast-feeding or pregnant * before the administration of lymphoseek, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical * is scheduled for surgery and/or another invasive procedure other than the primary surgical intervention within the 3 days after lymphoseek administration * has received an investigational product within the 30 days prior to lymphoseek administration
comparative effectiveness and cost-effectiveness of chuna manual therapy for chronic neck pain

Conditions: Chronic Neck Pain

Summary: a multi-center randomized controlled trial assessing the comparative effectiveness and cost-effectiveness of chuna manual therapy for chronic neck pain

a multi-center randomized controlled, parallel, assessor-blinded trial will be conducted to evaluate the comparative clinical effectiveness and cost-effectiveness of chuna manual therapy for chronic neck pain patients compared to usual care as assessed using pain, functional disability, health-related quality of life, economic evaluation, and safety measures.

Eligibility criteria:
inclusion criteria: * chronic neck pain patients (with pain duration of 3 months or longer) * patients with numeric rating scale (nrs) of radicular pain ≤ neck pain in neck pain patients with or without radiculopathy * patients with nrs of neck pain ≥5 during the 3 days * patients who have agreed to trial participation and provided written informed consent exclusion criteria: * patients diagnosed with serious pathology(s) which may cause neck pain (e.g. spinal metastasis of tumor(s), acute fracture, spinal dislocation) * patients with history of neck surgery * patients with other chronic disease(s) which may interfere with treatment effect, safety, or interpretation of outcomes (e.g. chronic renal failure, vertebral artery complications, rheumatoid arthritis, down syndrome) * patients with progressive neurologic deficit or severe neurologic symptoms such as spinal cord injury * patients with severe mental illness * patients currently taking steroids, immunosuppressants, medicine for mental illness or other medication(s) that may interfere with study results * patients who have received chuna manual therapy or physical therapy, medicine such as nonsteroidal anti-inflammatory drugs (nsaids), or treatment(s) that may influence pain within the past week * pregnant patients or patients with plans of pregnancy * patients participating in other clinical studies or otherwise deemed unsuitable by the researchers
wavelight® refractive flap accuracy study

Conditions: Refractive Error

Summary: the purpose of this study is to evaluate the accuracy of the wavelight fs200 femtosecond laser, as assessed by 1 day and 1 month post-operative optical coherence tomography (oct) anterior segment corneal measurements compared to pre-operative flap thickness target.


Eligibility criteria:
inclusion criteria: * willing and able to understand and sign an informed consent form. * have refractive error (in both eyes) that requires refractive surgery. * willing to undergo lasik surgery using the wavelight® refractive suite. * myopia between 0.00 to -12.0 diopters pre-operatively. * astigmatism between 0.00 to +6.00 diopters pre-operatively. * willing and able to attend post-operative examinations per protocol schedule. * other protocol-defined inclusion criteria may apply. exclusion criteria: * participation in a clinical study within the last 30 days. * history of previous corneal surgery in either eye. * multifocal ablations in either eye. * prk or ptk surgery in either eye. * suffering from acute or recurring eye diseases in either eye, such as corneal ulcers, cataract, etc. * any ocular disease and/or condition that, in the investigator's clinical judgment, may put subject at significant risk, compromise study results, or interfere significantly with subject's participation in the study. * unable to discontinue contact lens wear as specified in protocol. * history of herpes simplex or herpes zoster keratitis. * active ocular rosacea. * lyme disease. * severe ocular allergies. * other medical conditions and use of medications as specified in protocol. * pregnant or planning to become pregnant during the study. * other protocol-specified exclusion criteria may apply.

Keywords: nearsighted astigmatism lasik refractive surgery wavelight
vaginal tactile imaging for pelvic floor prolapse

Conditions: Pelvic Organ Prolapse

Summary: the investigators will analyze biomechanical transformation of pelvic floor tissues and support structures under affected pelvic floor conditions and repaired states after the surgery.


Eligibility criteria:
inclusion criteria: 1. subject is female of 21 years or older, and 2. no prior pelvic floor surgery, and 3. one of the following: normal pelvic floor conditions, or pop stage i affecting one or more vaginal compartment, or pop stage ii affecting one or more vaginal compartment, or pop stage iii affecting one or more vaginal compartment, or pop stage iv affecting one or more vaginal compartment exclusion criteria: 1. active skin infection or ulceration within the vagina 2. presence of a vaginal septum; 3. active cancer of the colon, rectum wall, cervix, vaginal, uterus or bladder; 4. ongoing radiation therapy for pelvic cancer; 5. impacted stool; 6. significant pre-existing pelvic pain including levator ani syndrome, severe vaginismus or vulvadynia; 7. severe hemorrhoids; 8. significant circulatory or cardiac conditions that could cause excessive risk from the examination as determined by attending physician; 9. current pregnancy.
sirs-eswt trial: shoulder internal rotator spasticity trial treated with extracorporeal shock wave therapy trial

Conditions: Stroke; Muscle Spasticity

Summary: extracorporeal shock wave therapy (eswt) has shown potential in reducing post-stroke limb spasticity. this study aims to evaluate the efficacy of focused eswt on shoulder internal rotator spasticity in post-stroke patients.

this study aimed to evaluate the effects of focused extracorporeal shock wave therapy (eswt) on shoulder internal rotator spasticity in stroke patients. participants were randomized into two groups: an experimental group receiving targeted eswt on specific shoulder internal rotators, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions. the efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, and ultrasound strain elastography. the outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on shoulder function and spasticity in stroke survivors.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older with unilateral cerebral stroke. * restricted passive external rotation of the spastic shoulder by more than 20 degrees. * a modified ashworth scale score of 1 or higher for shoulder internal rotator spasticity. * stable medical condition and vital signs. * clear consciousness, able to follow instructions. exclusion criteria: * history of two or more strokes, traumatic brain injury, brain tumors, or other cerebral disorders. * coexisting central nervous system disorders (e.g., spinal cord injury, parkinson's disease) or other musculoskeletal conditions affecting muscle tone assessment. * ineligibility for shock wave intervention due to malignancies, coagulation disorders, localized infections, or presence of a pacemaker. * prior shock wave intervention or botulinum toxin injection for post-stroke spasticity within the past three months. * inability to participate in interventions or functional assessments due to cognitive, consciousness, or language impairments.

Keywords: stroke spasticity shock wave shoulder
home-based health management of chronic obstructive lung disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease; Emphysema; Pulmonary Rehabilitation

Summary: regular physical activity has been found to be important in maintaining health and well-being in people with copd. the purpose of this study is to test new technology and health coaching aimed to help people with copd become more physically active in their daily lives.

this study consists of a home-based pulmonary rehabilitation system. the system consists of a tablet computer, pulse oximeter, activity monitor and weekly telephone health coach calls. the rehabilitation period lasts 8 weeks. this is a randomized trial with two groups. group a will complete the study activities during the first 8 weeks of the study followed by a period of observation. group b will complete 8 weeks of observation followed by 8 weeks of rehabilitation.

Eligibility criteria:
inclusion criteria: * • men and women age 40 years and older * current or former smoker of at least 10 pack-years * diagnosis of global initiative for chronic lung disease (gold) stage ii, iii or iv copd as documented by pulmonary function * are eligible for pulmonary rehabilitation exclusion criteria: * • unable to perform mild exercises * patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency), are planning to move out of the state, are not living in the healthcare area. * patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).
dapagliflozin after transcatheter aortic valve implantation

Conditions: Aortic Stenosis; Transcatether Aortic Valve Implantation

Summary: pragmatic, controlled, prospective, randomized, open-label (open-label), evaluator-blind clinical trial (probe design) that will analyze the benefits of dapagliflozin treatment in patients with severe aortic stenosis discharged after implantation of an aortic valve prosthesis transcatheter (tavi).

patients discharged after tavi, with a history of heart failure (hf) plus depressed left ventricular ejection fraction (lvef ≤ 40%) or diabetes mellitus (dm) or glomerular filtration rate (gfr) between 25 and 75 ml/min/1.73 m2, will be randomized (1:1) before hospital discharge to receive treatment with dapagliflozin 10 mg/day or no dapagliflozin (no placebo). only variables available during routine clinical practice will be collected and there will be no additional tests. the incidence of clinical events and adherence to the dapagliflozin arm will be documented at 2 time-points (3 ± 1 months and 12 months) by phone calls and review of medical records.

Eligibility criteria:
inclusion criteria: * severe aortic stenosis underwent tavi * prior heart failure admission and one of the following criteria: 1. left ventricular ejection fraction ≤ 40% or 2. diabetes mellitus or 3. estimated glomerular filtrate rate 25-75 ml/min/1.73 m2 exclusion criteria: * known allergy or intolerance to sglt2 inhibitors. * concomitant therapy with sulfonylurea or sglt2 inhibitors.. * systolic blood pressure \< 100 mmhg or diastolic blood pressure \< 50 mmhg. * an estimated glomerular filtration rate (gfr) below 25 ml per minute per 1.73 m2. * chronic cystitis and/or recurrent urinary tract infections (2 or more in the last year) * poor control of diabetes mellitus that requires sglt-2 inhibitor prescription on discharge according to treating physician judge. * any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year). * pregnant or breast-feeding patients * patients participating in other clinical trials.

Keywords: aortic stenosis tavi dapagliflozin